KOHEN AVOCATS · PARIS, FRANCE
60 minutes tonight kratom episode: How should consumers read supplement claims?

Hassan Kohen is a Paris-based lawyer admitted to the Paris Bar (Avocat au Barreau de Paris). Initial strategic analysis: €80 incl. VAT, personal reply within 24 hours.

100% confidential · Legal professional privilege · No obligation

Article generated by artificial intelligence, through a process designed and supervised by the firm

Sources: U.S. court opinions and official U.S. government publications, read for this article

Maître Hassan KOHEN, avocat au Barreau de Paris
Hassan KOHEN
Attorney at the Paris Bar

60 minutes tonight kratom episode: How should consumers read supplement claims?

Speak to a lawyer 06 89 11 34 45

The November 15 edition of 60 Minutes listed a report on kratom, a botanical sold in a range of products in the United States. A viewer looking at a bottle afterward may see a supplement-style panel, an ingredient name, and statements about how the product affects the body. Those features answer different questions. They do not, by themselves, establish that the Food and Drug Administration has approved the product or determined that it can lawfully be sold as a dietary supplement.

On its public information page, the FDA says that kratom is not lawfully marketed as a dietary supplement and that there are no kratom drug products legally on the U.S. market. The agency also warns of serious adverse events while acknowledging important gaps in the research. That is the agency’s federal position, not a finding about any particular bottle or seller.

Federal labeling rules nevertheless offer a useful way to examine claims made for products presented as supplements. Recent decisions involving different products show why the exact label, the evidence behind a claim, and the stage of a lawsuit matter. The discussion below is general in scope: it describes checks useful in comparable situations and makes no findings about the businesses named in those decisions. It does not turn those cases into rulings about kratom.

I. What does a supplement label tell you about a kratom product?

A. Start with the FDA’s position, then identify the actual product

The first check is the product itself: the name on the package, its form, the ingredients it lists, and what the seller says it is supposed to do. Kratom can appear in more than one presentation, and a powder, capsule, liquid, or extract should not be treated as interchangeable merely because each uses the same plant name. A buyer can compare the label with the seller’s description and preserve both before deciding what the claim actually promises.

In its public guidance on kratom, the FDA says it has concluded that kratom is a new dietary ingredient for which the available information does not provide reasonable assurance against a significant or unreasonable risk of illness or injury. On that basis, the agency says dietary supplements containing it are adulterated under federal law and are not lawfully marketed as dietary supplements. It separately says kratom cannot lawfully be added to conventional food under its food-additive determination. The page is agency guidance explaining the FDA’s position; it is not a court judgment about a particular product.

The same FDA page says there are no prescription or over-the-counter kratom drug products legally on the U.S. market. A statement that a product is on a shelf, that it is natural, or that people have used it for a long time is not the same as an FDA approval for a medical use. Nor does a seller’s choice of a supplement-style label settle the ingredient’s legal status. The practical answer to the initial question is therefore no: a Supplement Facts panel is not proof that the agency has approved kratom or regards a kratom supplement as lawfully marketed.

The FDA warns consumers not to use kratom because of risks including liver toxicity, seizures, and substance use disorder. It also reports that deaths have been associated with kratom use in some cases, usually alongside other drugs, while the contribution of kratom to those deaths remains unclear. That distinction matters. An association in a public-health warning does not establish why a particular person became ill, what was in a particular product, or whether a particular seller caused an injury.

The FDA says that the naturally occurring compound 7-hydroxymitragynine, often abbreviated 7-OH, is a minor constituent of natural kratom leaves and that products involving it raise separate questions. The amount or form a person encounters cannot be inferred simply from the word kratom on an advertisement. Preserve the ingredient and serving information and give it to a health professional when discussing an exposure, including any other substances or medicines taken. A photograph of the complete package is more useful than a picture of its front alone.

Federal rules are only one layer. The FDA notes that states may have their own kratom regulations or prohibitions. A package purchased in one state and shipped to another can raise questions about both the product and the location of the transaction. Check the applicable state rules separately instead of assuming that a federal warning either proves every state has banned possession or means every state treats the product identically.

If someone is experiencing a concerning reaction, the immediate question is medical rather than evidentiary. Share what was taken, the approximate amount and time if known, and the package or product description with a qualified health professional. Do not discard treatment records merely because the label is missing; conversely, do not treat a label or a television report as a medical diagnosis. The FDA guidance also identifies its adverse-event reporting systems as a way consumers and professionals can report reactions.

B. Read the identity, ingredients, serving size, and seller information separately

For packaged food, 21 C.F.R. § 101.3 sets federal requirements for an identity statement and provides how dietary supplements are to be identified. A statement of identity helps a reader understand what the package purports to contain. It does not prove that the stated category is legally available to every ingredient. That qualification is especially important where the FDA has taken the position described above on kratom.

Look next at the serving information. Federal 21 C.F.R. § 101.36 addresses nutrition labeling for dietary supplements, including serving size and the amount of dietary ingredients per serving, with specified exceptions and special rules. A number printed for one serving may refer to more than one capsule or a measured portion of liquid. Comparing two packages requires checking the unit first, not just comparing the largest number on each front label.

For example, if one label describes an amount per two capsules and another describes an amount per capsule, compare the amounts using the units actually printed on each package. If a liquid label gives a volume, do not silently treat that volume as the weight of the plant or of an individual compound. The label may supply a concentration or other detail, but the meaning of that detail still depends on the form of the product. These comparisons help identify what information is missing; they do not establish a safe amount or verify the contents.

The same regulation has particular provisions for liquid extracts, dried extracts, and proprietary blends. Depending on the form, an amount may describe the weight or volume of an extract, rather than the amount of every constituent in it. For a blend, the rule provides for a total amount of the covered ingredients and their order by weight. It does not follow that the label reveals the precise amount of each constituent or establishes what a particular dose will do to an individual.

Federal 21 C.F.R. § 101.4 addresses ingredient declarations, including where an ingredient list appears and how botanicals in dietary supplements are identified. For the products covered by that rule, the plant part is relevant to the declaration, subject to the stated exceptions. Compare the ingredient list with the nutrition panel: some source ingredients may appear in the panel rather than being repeated outside it. A reader should keep both panels together when preserving the label.

An ingredient name is not the same thing as an independent laboratory result. It tells the reader what the label represents; it cannot by itself establish that a particular package contains precisely that material, the amount advertised, or no contaminant. If a question later arises about a specific lot, preserve whatever identifies that lot and the condition of the package. Avoid opening or transferring remaining contents solely to make an informal test if doing so would interfere with safe handling or destroy useful identifying information.

Finally, identify the business named on the package and the role the label describes. Under federal 21 C.F.R. § 101.5, a packaged food label generally must state the name and place of business of the manufacturer, packer, or distributor, with qualifications where the named person is not the manufacturer. The retailer, the distributor on the label, and the actual manufacturer may be different entities. The label is a starting point for that distinction, not proof that each performed the same role.

Keep the receipt, order confirmation, delivery record, and any product page that influenced the purchase. A page can change, so a dated copy showing the exact version seen is useful. If the product was purchased for someone else, record who bought it, who used it, and which package each person is discussing. Those facts help prevent a later comparison of different products or different versions of the same packaging.

A supplement-style layout can therefore help organize a factual inquiry: identity on one panel, ingredients and quantities on another, and the named business elsewhere. It is not a seal of federal approval. In the particular case of kratom, the FDA’s stated position on lawful marketing remains the starting point even if a package imitates the appearance of a familiar supplement.

II. How do claims on a label become evidence in a consumer dispute?

A. Separate a statement about the body from a promise to treat a disease

Read the words a seller actually used. A general statement about the body’s structure or function is different from a claim that a product diagnoses, treats, cures, or prevents a disease. The distinction turns on the statement and its context, not simply on whether a disclaimer appears in small print. A product name, image, nearby explanation, and cited publication can all contribute context when a claim is evaluated.

Federal 21 C.F.R. § 101.93 describes certain statements on dietary supplements, the associated disclaimer requirements, and criteria for disease claims. It permits specified structure-or-function statements subject to the rule’s conditions; it also explains that a disease claim can place a product marketed as a supplement under drug regulation unless an applicable authorized health-claim exception applies. That rule does not make a kratom product lawful merely because it carries a disclaimer or uses a structure-or-function phrase.

For a reader, the practical step is to preserve the complete representation: the prominent claim, the words immediately around it, the package panel, and any disclaimer to which it points. Do the same for an online listing and any advertisement that led to it. A later summary such as “the seller said it was safe” may be too broad to show what was actually promised or what the reader understood when buying.

In Scheibe v. ProSupps USA, LLC, No. 23-3300 (9th Cir. June 23, 2025), the United States Court of Appeals for the Ninth Circuit reversed dismissal of California consumer claims alleging inaccurate nutrient information on a different dietary supplement. At the pleading stage, the court concluded that the alleged preliminary laboratory test supported a reasonable inference sufficient to survive the asserted federal preemption ground; the opinion did not decide final liability. For a buyer, the decision shows why the exact label and available testing information can matter, while a preliminary allegation remains different from a finding that a product was mislabeled.

The distinction between a claim and proof runs through that decision. The court considered what the plaintiff alleged, the federal labeling framework, and why the alleged testing was sufficient at that procedural stage. It did not say that a single test establishes every label violation or that a purchaser must conduct the same test before raising any question. A buyer who has no test can still preserve the package and identify what is known and unknown about its contents.

In Montera v. Premier Nutrition Corp., No. 22-16375 (9th Cir. August 6, 2024), the United States Court of Appeals for the Ninth Circuit reviewed a trial involving a different supplement and claims under New York consumer law. The court affirmed the liability determination and sent the statutory-damages award back for further consideration, while reversing the award of prejudgment interest. For a consumer, the decision illustrates that evidence about a specific effectiveness claim and the applicable state law can matter, but it does not establish that a different product’s claim is false.

That case reached a different stage from the preliminary decision in Scheibe: it followed a trial with evidence about the representations and the product’s ingredients. When reading any case report, check whether the court was considering allegations, a motion, trial evidence, or a final judgment. The same word, claim, can describe what one party says at the beginning and what a court ultimately determines after evidence has been tested.

Do not infer from either supplement decision that kratom was studied in those cases. The FDA’s guidance on kratom and the courts’ holdings about other products have different subjects. A buyer’s useful comparison is methodological: identify the representation, its audience, the product involved, and the evidence relevant to that representation before drawing a conclusion about a particular transaction.

B. Organize the purchase, representations, and any injury as separate questions

A consumer dispute can involve more than one kind of alleged loss. A person may question a purchase because the product was not as represented, or may report a physical reaction, or both. Those are not interchangeable. A record showing what was paid can be useful for the first question, while medical records, the actual product, timing, other exposures, and appropriate expert analysis may matter to the second. None of those items alone automatically proves causation or liability.

In Bowen v. Energizer Holdings, Inc., No. 23-55116 (9th Cir. October 1, 2024), the United States Court of Appeals for the Ninth Circuit reversed a dismissal for lack of federal Article III standing in a dispute about a different product, sunscreen. The court concluded that the purchaser had established economic injury at that stage and that disputed facts remained about the challenged representations; it remanded for further proceedings rather than deciding liability. For a buyer, the decision shows why the alleged purchase, the representation encountered, and the claimed economic loss should be documented separately from an alleged physical injury.

The court’s decision concerned the record and procedural posture before it. It did not turn an FDA document about a different chemical into a ruling about kratom. Nor did it decide that every dissatisfied purchaser will have standing or prevail under every state’s law. It is an example of how a federal court analyzed a claimed economic injury when reviewing that particular dismissal.

Start a record with the date and place of purchase, the price paid, the quantity, and the exact product version. If a transaction was online, save the confirmation and the page or advertisement as it appeared when the decision to buy was made. If the purchase was in a store, a receipt and photographs of the front, back, sides, and lot information can connect the purchase to the package. Keep the originals as well as digital copies where practical.

Next, write down the specific statement at issue and where it appeared. A short note can distinguish a statement printed on the bottle from a statement made on a website, a retailer’s sign, or an individual conversation. Identify whether the statement concerned ingredients, quantity, a physical effect, a claimed treatment, or a refund. If the recollection is uncertain, say so in the record rather than filling gaps with language from a later advertisement.

If the purchase followed an online recommendation, distinguish the seller’s own product description from a third party’s statement. Save the date and location of each representation and whether the product page was the same one used for the transaction. If an advertisement changed after the purchase, keep both versions labeled by date. This creates a useful sequence without assuming that every later statement was seen by the buyer or that every speaker had the same relationship to the product.

Then separate observed facts from possible explanations. A person can record that a particular package was purchased, that a symptom was noticed, and that a health professional was consulted. Whether an ingredient was present at a particular concentration, whether the product caused the symptom, and whether any legal duty was breached may require additional evidence. Avoid attributing a cause based only on a headline or on similarities between two labels.

Where a laboratory result is available, keep the report with the sample’s identity, collection information, method, and any stated limits. A result about one sample should not automatically be described as a result for every bottle or batch. In a labeling dispute, the precise federal requirement, the state claim, and the procedural stage can affect how a court treats testing evidence, as the Scheibe decision illustrates. A consumer does not need to turn a preliminary record into a scientific conclusion.

A request to a seller should identify the transaction and the precise issue rather than assume an answer. A buyer can ask which entity supplied the product, request a copy of the label or relevant batch information, and keep the reply with the purchase records. The seller’s response is evidence of what the seller said; it is not an agency determination or a judicial finding. A refund, if offered, should be considered in light of its actual terms and any other concerns about the product.

If the person has a potential health concern, medical care and accurate disclosure to the treating professional take priority. Preserve bills and records without altering the container or taking a product again to reproduce an effect. A contemporaneous account of timing and other substances can help a professional understand the history, while a later legal assessment would still depend on the evidence and the law governing the particular claim.

Finally, identify the state connected with the transaction and any court proceeding before relying on a case from elsewhere. Scheibe concerns California consumer claims in the Ninth Circuit, Montera applies New York consumer law in a case reviewed by that circuit, and Bowen addresses federal standing in its own record. These decisions illuminate different questions. They do not supply a universal rule that a particular kratom purchase gives rise to a successful claim.

Conclusion

A supplement-style label can help a buyer identify what was represented, but it does not establish FDA approval or lawful marketing. The FDA says kratom is not lawfully marketed as a dietary supplement and warns of serious risks. Read the identity, ingredients, serving size, business information, and exact health claim together; preserve the purchase and any relevant medical records. The comparable decisions show why the facts, governing jurisdiction, and stage of a dispute must be kept distinct when evaluating what a label means.

📄 Official circular